Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

1.655 -0.035 (-2.07%)
Streaming Delayed Price Updated: 2:17 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 164,473
Open 1.740
Bid (Size) 1.650 (8)
Ask (Size) 1.660 (37)
Prev. Close 1.690
Today's Range 1.615 - 1.775
52wk Range 1.180 - 4.440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
From ProKidney
Via GlobeNewswire

Performance

YTD
-3.22%
-3.22%
1 Month
-15.99%
-15.99%
3 Month
-31.04%
-31.04%
6 Month
-57.35%
-57.35%
1 Year
-5.97%
-5.97%

More News

Read More
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
From ProKidney
Via GlobeNewswire
PROK Stock Earnings: ProKidney Beats EPS for Q2 2024
Via InvestorPlace
PROK Stock Earnings: ProKidney Reported Results for Q4 2023
Via InvestorPlace
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
Via InvestorPlace
ProKidney to Participate in the UBS Virtual Organ Restoration Day
From ProKidney
Via GlobeNewswire
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
Over $30M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
From ProKidney
Via GlobeNewswire
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.